Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis.
Kubota
Tetsuo
T
Tokyo Medical and Dental University Graduate School of Health Sciences, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan. tetsuo.kubota.mtec@tmd.ac.jp
Nii
Tokiko
T
Nanki
Toshihiro
T
Kohsaka
Hitoshi
H
Harigai
Masayoshi
M
Komano
Yukiko
Y
Sugihara
Takahiko
T
Nonomura
Yoshinori
Y
Hirose
Wataru
W
Nagasaka
Kenji
K
Sakurai
Tetsushi
T
Miyasaka
Nobuyuki
N
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000917:Antibody Formation / Q000276:immunology*; D018501:Antirheumatic Agents / Q000276:immunology* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology*; D000068800:Etanercept; D006801:Humans; D007121:Immunocompetence / Q000187:drug effects / Q000276:immunology*; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D007252:Influenza Vaccines / Q000276:immunology*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007252:Influenza Vaccines; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept